You have successfully logged out.

search
menu
close
What are you looking for?
close close

Peripheral Angioplasty

Combination therapy for endovascular procedures

Leave almost nothing behind by using our proven SeQuent® Please OTW DCB in combination with VascuFlex® LOC multiple stent systems for spot and focal stenting.

Undress the full metal jacket

SeQuent® Please OTW: A fruitful formulation

Paclitaxel with a drug dose of 3 μg/mm²

  • Proven and effective drug dose [1]
  • Homogeneous coating even in the balloon folds [2]

 

Resveratrol as hydrophilic excipient

  • Naturally occurring, plant based substance found e.g. in red grapes & raspberries
  • Acts as hydrophilic spacer and makes Paclitaxel bioavailable
  • Enables drug transfer into vessel wall [2]

CONSEQUENT randomized controlled trial

  • 153 patients (78 DCB vs. 75 POBA)
  • Rutherford 2-4 (95 % Grade 3-4)
  • Diameter stenosis pre-procedure: 76.6 ± 18.1 %
  • TASC C/D lesions: 23.5 %
  • Mean lesion length 13.2 ± 10.4 cm
  • Positive remodeling (LLL <0.00 mm) in DCB group: 36.5 %
  • Predilatation: in only 55.6 % of cases
  • Bailout stenting: 16.3 % (similar in both groups)
  • Primary endpoint: 6-month angiographic late lumen loss
  • Secondary endpoints: TLR, binary restenosis (> 50 %, PSVR > 2.4), walking distance, ABI at 6, 12 and 24 months

 

close
CONSEQUENT randomized controlled trial: Mean lesion length table play_circle
CONSEQUENT randomized controlled trial: 6 month late lumen loss table play_circle
CONSEQUENT randomized controlled trial: 24 month TLR rate table play_circle
CONSEQUENT randomized controlled trial: 24 month mean walking distance table play_circle

VascuFlex® Multi-LOC: Spot your lesions with short stents only!

  • Six short stents on one delivery system
  • Cover lesions only where it is really needed
  • Maintain natural vessel movement
  • Avoid full metal jackets

 

Features

  • Short self-expanding Nitinol stents of 13 mm length each
  • Stents with high radial force for highly calcified lesions [2]
  • 5-8 mm stent diameters for SFA and popliteal arteries
  • 0.035” guidewire compatibility; 6F sheath compatibility

LOCOMOTIVE extended study: 12-month data [8]

  • 357 patients
  • 71.1 % Rutherford stages 3 to 5
  • Lesions in SFA and popliteal artery (segments 1 to 3) with vessel diameter: 5.5 ± 1.1 mm
  • Average lesion lengths: 16.0 ± 9.7 cm
  • Calcification: 85.7 %
  • Chronic total occlusion: 31.4 %
  • TASC C&D lesions: 44.5 %
  • TLR rate at 6 months (primary endpoint): 4.5 % (Revaskularisation rate of the target lesion)
  • Secondary endpoints: TLR at 12 months, patency (Duplex ultrasound), Rutherford classification, amputation rate, ABI and walking distance at 6 and 12 months

 

Learn more about related products

Product Picture CW Enlargement

SeQuent® Please OTW

Peripheral drug coated balloon catheter

Product Picture Enlargement CW

VascuFlex® Multi-LOC

Spot stenting system

Product Picture CW Enlargement

VascuFlex® 2-LOC

Focal stenting system

Product Picture CW Enlargement

VascuFlex® 3-LOC

Focal stenting system

Get in touch with our Interventional Vascular Therapy experts

Interventional Vascular Therapy Contact Form

[1] Katsanos K et al. in J Endovasc Ther. 2016 Apr;23(2):356-70

[2] Data on file at B. Braun

[3] Albrecht T et al. Cardiovasc Intervent Radiol. 2018 Jul;41(7):1008-1014

[4] Schröder H Catheterization and Cardiovascular Interventions, Volume 86, Issue 2 August 2015 Pages 278-286

[5] Werk M et al. Circ Cardiovasc Interv. 2012;5(6):831-840

[6] Scheinert D et al. JACC Cardiovasc Interv. 2014;7(1):10-19

[7] Zeller T et al. JACC Cardiovasc Interv. 2015;8(12):1614-1622

[8] Amendt K, et al. Vasa (2020), 1-8.doi.org/10.1024/0301-1526/a000927

Stay connected with My B. Braun

With your personalized account, your online experience will be easier, more comfortable and safe.

person_outline My B. Braun